Gut

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peters, F T M
Right arrow Articles by Kleibeuker, J H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peters, F T M
Right arrow Articles by Kleibeuker, J H
Gut 1999;45:489-494 ( October )

Article

Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study F T M Petersa, S Ganeshc, E J Kuipersd, W J Sluiterb, E C Klinkenberg-Knold, C B H W Lamersc, J H Kleibeukera

a Department of Gastroenterology and Hepatology, University Hospital Groningen, Groningen, The Netherlands, b Department of Endocrinology, University Hospital Groningen, Groningen, The Netherlands, c Department of Gastroenterology and Hepatology, University Hospital Leiden, Leiden, The Netherlands, d Department of Gastroenterology and Hepatology, Free University Hospital Amsterdam, Amsterdam, The Netherlands

Correspondence to: Dr F T M Peters, University Hospital Groningen, Department of Gastroenterology, PO Box 30.001, 9700 RB Groningen, The Netherlands.

Accepted for publication 27 April 1999

BACKGROUND---Barrett's oesophagus, columnar metaplasia of the epithelium, is a premalignant condition with a 50-100-fold increased risk of cancer. The condition is caused by chronic gastro-oesophageal reflux. Regression of metaplasia may decrease the cancer risk.
AIMS---To determine whether elimination of acid gastro-oesophageal reflux induces a regression of metaplastic epithelium.
METHODS---Sixty eight patients with acid reflux and proven Barrett's oesophagus were included in a prospective, randomised, double blind study with parallel groups, and were treated with profound acid secretion suppression with omeprazole 40 mg twice daily, or with mild acid secretion suppression with ranitidine 150 mg twice daily, for 24 months. Endoscopy was performed at 0, 3, 9, 15, and 24 months with measurement of length and surface area of Barrett's oesophagus; pH-metry was performed at 0 and 3 months. Per protocol analysis was performed on 26 patients treated with omeprazole, and 27 patients treated with ranitidine.
RESULTS---Omeprazole reduced reflux to 0.1%, ranitidine to 9.4% per 24 hours. Symptoms were ameliorated in both groups. There was a small, but statistically significant regression of Barrett's oesophagus in the omeprazole group, both in length and in area. No change was observed in the ranitidine group. The difference between the regression in the omeprazole and ranitidine group was statistically significant for the area of Barrett's oesophagus (p=0.02), and showed a trend in the same direction for the length of Barrett's oesophagus (p=0.06).
CONCLUSIONS---Profound suppression of acid secretion, leading to elimination of acid reflux, induces partial regression of Barrett's oesophagus.


Keywords: acid reflux; Barrett's oesophagus; omeprazole; regression

© 1999 by Gut


This article has been cited by other articles:


Home page
 Therapeutic Advances in GastroenterologyHome page
M. S. Smith and C. J. Lightdale
Review: Barrett's esophagus and the increasing role of endoluminal therapy
Therapeutic Advances in Gastroenterology, September 1, 2008; 1(2): 121 - 142.
[Abstract] [PDF]

Home page
 DTBHome page
Dilemmas in managing Barrett's oesophagus
DTB, September 1, 2006; 44(9): 69 - 72.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
P Sharma, S Wani, A P Weston, A Bansal, M Hall, S Mathur, A Prasad, and R E Sampliner
A randomised controlled trial of ablation of Barrett's oesophagus with multipolar electrocoagulation versus argon plasma coagulation in combination with acid suppression: long term results.
Gut, September 1, 2006; 55(9): 1233 - 1239.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
P. Lao-Sirieix, A. Roy, C. Worrall, S. L. Vowler, S. Gardiner, and R. C. Fitzgerald
Effect of Acid suppression on molecular predictors for esophageal cancer.
Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 288 - 293.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
H Barr, N Stone, and B Rembacken
ENDOSCOPIC THERAPY FOR BARRETT'S OESOPHAGUS
Gut, June 1, 2005; 54(6): 875 - 884.
[Full Text] [PDF]

Home page
 NEJMHome page
P. C. Enzinger and R. J. Mayer
Esophageal Cancer
N. Engl. J. Med., December 4, 2003; 349(23): 2241 - 2252.
[Full Text] [PDF]

Home page
 GutHome page
H Barr
Endoscopic surveillance of patients with Barrett's oesophagus
Gut, September 1, 2002; 51(3): 313 - 314.
[Full Text]

Home page
 JAMAHome page
N. Shaheen and D. F. Ransohoff
Gastroesophageal Reflux, Barrett Esophagus, and Esophageal Cancer: Scientific Review
JAMA, April 17, 2002; 287(15): 1972 - 1981.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. J. Spechler
Barrett's Esophagus
N. Engl. J. Med., March 14, 2002; 346(11): 836 - 842.
[Full Text] [PDF]

Home page
 GutHome page
F T M PETERS
Proton pump inhibitors for Barrett's oesophagus
Gut, July 1, 2000; 47(1): 154a - 155.
[Full Text] [PDF]

Home page
 GutHome page
G TRIADAFILOPOULOS
Proton pump inhibitors for Barrett's oesophagus
Gut, February 1, 2000; 46(2): 144 - 146.
[Full Text] [PDF]

Home page
 GutHome page
N A SHEPHERD
Barrett's oesophagus and proton pump inhibitors: a pathological perspective
Gut, February 1, 2000; 46(2): 147 - 149.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 1999 BMJ Publishing Group Ltd & British Society of Gastroenterology